Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1381P - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

Date

16 Sep 2021

Session

ePoster Display

Presenters

Markus Moehler

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

M. Moehler1, J.A. Ajani2, J. Kuzdzal3, T. Zander4, E. Van Cutsem5, G. Piessen6, G.A. Mendez7, J. Feliciano8, S. Motoyama9, A. Lièvre10, H. Uronis11, E. Elimova12, C. Grootscholten13, K. Geboes14, J. Zhang15, S. Soleymani16, M. Lei17, K. Kondo18, J. Cleary19, R.J. Kelly20

Author affiliations

  • 1 Dept. Medicine, Johannes-Gutenberg University Clinic, 55131 - Mainz/DE
  • 2 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Thoracic Surgery, Department of Thoracic Surgery, Jagiellonian University, John Paul II Hospital, 31-202 - Krakow/PL
  • 4 Gastrointestinal Tumors, University Hospital of Cologne, 50937 - Cologne/DE
  • 5 Gastroenterology / Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KULeuven, 3000 - Leuven/BE
  • 6 Department Of Digestive And Oncological Surgery, University Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, F-59000 - Lille/FR
  • 7 Oncology Department, Fundacion Favaloro, C1264AAA - Buenos Aires/AR
  • 8 Hematology Oncology, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21224 - Baltimore/US
  • 9 Esophageal Surgery, Akita University Hospital, 1-1-1 Hondo - Akita/JP
  • 10 Gastroenterology And Gi Oncology, CHU Pontchaillou, 35000 - Rennes/FR
  • 11 Medical Oncology, Duke University Institute, 27710 - Durham/US
  • 12 Medical Oncology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 13 Gastrointestinal Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 14 Service Of Digestive Oncology, UZ Gent, 9000 - Gent/BE
  • 15 Biometrics, Bristol Myers Squibb, 08540 - Princeton/US
  • 16 Biostatistics, Bristol Myers Squibb, 08540 - Princeton/US
  • 17 Clinical Research, Bristol Myers Squibb, 08540 - Princeton/US
  • 18 Ww Medical Lead, Bristol Myers Squibb, 08540 - Princeton/US
  • 19 Medical Oncology, Dana Farber Cancer Institute, MA 02215 - Boston/US
  • 20 Medical Oncology, The Charles A. Sammons Cancer Center at Baylor University Medical Center, TX 75246 - Dallas/US
More

Abstract 1381P

Background

The risk of recurrence after neoadjuvant CRT followed by surgery (trimodality therapy) remains high in EC/GEJC. Statistically significant and clinically meaningful improvement in disease-free survival (DFS) was demonstrated for nivolumab vs placebo (median, 22.4 vs 11.0 months [mo]; HR 0.69; 96.4% CI 0.56–0.86; P = 0.0003) with a well-tolerated safety profile in patients with resected EC/GEJC who received neoadjuvant CRT in the global, randomized, phase III CheckMate 577 study. Here, we report efficacy and safety with an additional 8 mo follow-up.

Methods

Adults with resected (R0) stage II/III EC/GEJC who received neoadjuvant CRT and had residual pathologic disease were randomized 2:1 to nivolumab 240 mg or placebo Q2W for 16 weeks, followed by nivolumab 480 mg or placebo Q4W. Maximum treatment duration was 1 year. The primary endpoint was DFS. Exploratory endpoints included distant metastasis–free survival (DMFS).

Results

794 patients were randomized (nivolumab, 532; placebo, 262). In both groups, approximately 70% of patients had adenocarcinoma and almost 60% had a pathologic lymph node status ≥ypN1. With a minimum follow-up of 14 mo, adjuvant nivolumab showed a doubling of median DFS vs placebo (Table). DFS benefit was observed across multiple subgroups. Adjuvant nivolumab showed approximately 13 mo improvement in median DMFS compared to placebo (Table). The safety profile was consistent with that reported previously and most treatment-related adverse events (TRAEs) were grade 1 or 2 (Table). Table: 1381P

Efficacy Nivolumab N = 532 Placebo N = 262
Median DFS, mo (95% CI) 22.4 (16.9–33.6) 10.4 (8.3–13.9)
HR (95% CI) 0.67 (0.55–0.81)
12 mo DFS rate, % (95% CI) 62 (57–66) 45.5 (39–51)
Median DMFS, mo (95% CI) 29.4 (23.7–36.6) 16.6 (11.4–24.9)
HR (95% CI) 0.71 (0.58–0.87)
12 mo DMFS rate, % (95% CI) 68 (64–72) 56 (49.5–62)
Safety, n (%) N = 532 N = 260
Any-grade TRAEs 379 (71) 122 (47)
Grade 3–4 74 (14) 16 (6)
Serious TRAEs 41 (8) 7 (3)
Grade 3-4 31 (6) 3 (1)
Any-grade TRAEs leading to discontinuation 49 (9) 8 (3)
Grade 3-4 26 (5) 7 (3)

Conclusions

With additional follow-up data, adjuvant nivolumab continues to demonstrate clinically meaningful efficacy and a well-tolerated safety profile, further supporting its use as a new standard of care for patients with resected EC/GEJC who received neoadjuvant CRT and have residual pathologic disease.

Clinical trial identification

NCT02743494.

Editorial acknowledgement

Legal entity responsible for the study

Bristol Myers Squibb.

Funding

Bristol Myers Squibb.

Disclosure

M. Moehler: Financial Interests, Personal, Other, Consulting or Advisory Role: Bayer; Financial Interests, Personal, Other, Consulting or Advisory Role: MSD; Financial Interests, Personal, Other, Consulting or Advisory Role: Merck Serono; Financial Interests, Personal, Other, Consulting or Advisory Role: Amgen; Financial Interests, Personal, Other, Consulting or Advisory Role: Taiho Pharmaceutical; Financial Interests, Personal, Other, Consulting or Advisory Role: Pfizer; Financial Interests, Personal, Other, Consulting or Advisory Role: Roche; Financial Interests, Personal, Other, Consulting or Advisory Role: Lilly; Financial Interests, Personal, Other, Consulting or Advisory Role: Servier; Financial Interests, Personal, Other, Consulting or Advisory Role: BeiGene; Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Amgen; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Merck Serono; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Roche; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Bayer; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: ASCO; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: German Cancer Society; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: MSD; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: ESMO; Financial Interests, Personal, Other, Honoraria: Amgen; Financial Interests, Personal, Other, Honoraria: Roche/Genentech; Financial Interests, Personal, Other, Honoraria: Merck Serono; Financial Interests, Personal, Other, Honoraria: MSD Oncology; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: AstraZenca/MedImmune; Financial Interests, Personal, Other, Honoraria: Servier; Financial Interests, Personal, Other, Honoraria: Pierre Fabre; Financial Interests, Personal, Other, Honoraria: Sanofi; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: Leap Therapeutics; Financial Interests, Institutional, Research Grant: Merck Serono; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: MSD. J.A. Ajani: Financial Interests, Personal, Other, Consulting or Advisory Role: American Cancer Society; Financial Interests, Personal, Other, Consulting or Advisory Role: BeiGene; Financial Interests, Personal, Other, Consulting or Advisory Role: Vaccinogen; Financial Interests, Personal, Other, Consulting or Advisory Role: Insys Therapeutics; Financial Interests, Personal, Other, Consulting or Advisory Role: Merck; Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Genentech; Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Taiho; Financial Interests, Personal, Research Grant: MedImmune; Financial Interests, Personal, Research Grant: Amgen; Financial Interests, Personal, Research Grant: Merck; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: Merck; Financial Interests, Personal, Other, Honoraria: Aduro Biotech; Financial Interests, Personal, Other, Honoraria: DAVA Pharmaceuticals; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Acrotech Biopharma; Financial Interests, Personal, Other, Honoraria: Zymeworks; Financial Interests, Personal, Other, Honoraria: Astellas Pharma; Financial Interests, Personal, Other, Honoraria: Amgen; Financial Interests, Personal, Other, Honoraria: Daiichi Sankyo; Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Taiho Pharmaceutical; Financial Interests, Personal, Research Grant: Roche/Genentech; Financial Interests, Personal, Research Grant: Amgen; Financial Interests, Personal, Research Grant: Lilly/ImClone; Financial Interests, Personal, Research Grant: Merck; Financial Interests, Personal, Research Grant: Delta-Fly Pharma; Financial Interests, Personal, Research Grant: Gilead Sciences; Financial Interests, Personal, Research Grant: Takeda; Financial Interests, Personal, Research Grant: ProLynx; Financial Interests, Personal, Research Grant: Zymeworks; Financial Interests, Personal, Research Grant: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Astellas Pharma; Financial Interests, Personal, Research Grant: Lilly. J. Kuzdzal: Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Roche. T. Zander: Financial Interests, Personal, Other, Consulting or Advisory Role: MSD; Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Other, Consulting or Advisory Role: ROCHE; Financial Interests, Personal, Other, Consulting or Advisory Role: Novartis. E. Van Cutsem: Financial Interests, Personal, Advisory Role: Array; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Personal, Advisory Board: Biocartis; Financial Interests, Personal, Advisory Board: Boehringer; Financial Interests, Personal, Advisory Board: Ingelheim; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Daiichi; Financial Interests, Personal, Advisory Board: Halozyme; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Merck KGaA; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Sirtex; Financial Interests, Personal, Advisory Board: Taiho; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: Bayer; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Ipsen; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant: Merck KGaA; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Servier. G. Piessen: Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Other, Consulting or Advisory Role: Nestle Health Sciences; Financial Interests, Personal, Other, Consulting or Advisory Role: MSD Oncology; Financial Interests, Personal, Other, Consulting or Advisory Role: Stryker; Financial Interests, Personal, Other, Consulting or Advisory Role: Roche; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Medtronic. G. Mendez: Financial Interests, Personal, Other, Consulting or Advisory Role: Merck; Financial Interests, Personal, Other, Consulting or Advisory Role: Roche; Financial Interests, Personal, Other, Consulting or Advisory Role: Servier; Financial Interests, Personal, Other, Consulting or Advisory Role: Lilly; Financial Interests, Personal, Other, Consulting or Advisory Role: MSD; Financial Interests, Personal, Other, Consulting or Advisory Role: Amgen; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: Servier; Financial Interests, Personal, Speaker’s Bureau: Lilly; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: Amgen; Financial Interests, Personal, Speaker’s Bureau: Bayer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Amgen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Servier; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bayer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Roche. J. Feliciano: Financial Interests, Personal, Other, Consulting or Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Consulting or Advisory Role: Merck; Financial Interests, Personal, Other, Consulting or Advisory Role: Genentech; Financial Interests, Personal, Other, Consulting or Advisory Role: Pfizer; Financial Interests, Personal, Other, Consulting or Advisory Role: Lilly; Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Merck; Financial Interests, Personal, Research Grant: Genentech; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Bristol Myers Squibb. S. Motoyama: Financial Interests, Personal, Other, Consulting or Advisory Role: Ono Pharmaceutical Co., Ltd.; Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceutical Co., Ltd. A. LIÈVRE: Financial Interests, Personal, Other, Honoraria: Advanced Accelerator Applications; Financial Interests, Personal, Other, Honoraria: Amgen; Financial Interests, Personal, Other, Honoraria: Bayer; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: HalioDx; Financial Interests, Personal, Other, Honoraria: Ipsen; Financial Interests, Personal, Other, Honoraria: Merck; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: Pierre Fabre; Financial Interests, Personal, Other, Honoraria: Sandoz; Financial Interests, Personal, Other, Honoraria: Servier; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Sanofi; Financial Interests, Personal, Other, Consulting or Advisory Role: Advanced Accelerator Applications; Financial Interests, Personal, Other, Consulting or Advisory Role: Amgen; Financial Interests, Personal, Other, Consulting or Advisory Role: Bayer; Financial Interests, Personal, Other, Consulting or Advisory Role: Ipsen; Financial Interests, Personal, Other, Consulting or Advisory Role: Merck; Financial Interests, Personal, Other, Consulting or Advisory Role: Novartis; Financial Interests, Personal, Other, Consulting or Advisory Role: Pierre Fabre; Financial Interests, Personal, Other, Consulting or Advisory Role: Sandoz; Financial Interests, Personal, Other, Consulting or Advisory Role: Servier; Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte; Financial Interests, Personal, Other, Consulting or Advisory Role: Roche; Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Personal, Research Grant: IntegraGen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Advanced Accelerator Applications; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bayer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Ipsen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Novartis; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Sandoz; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Servier; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Incyte; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Roche; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer. H. Uronis: Financial Interests, Personal, Other, Consulting or Advisory Role: AstraZeneca; Financial Interests, Institutional, Research Grant: Genentech/Roche; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Macrogenics; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Leap Therapeutics; Financial Interests, Personal, Other, Employment and Stocks (Immediate Family Member): GeneCentric. E. Elimova: Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Zymeworks; Financial Interests, Institutional, Other, Consulting fees: Adaptimmune; Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Board: Zymeworks; Financial Interests, Personal, Other, Spouse employee: Merck Vaccines. K. Geboes: Financial Interests, Personal, Other, Consulting or Advisory Role: Ipsen; Financial Interests, Personal, Other, Consulting or Advisory Role: MSD; Financial Interests, Personal, Other, Consulting or Advisory Role: Servier; Financial Interests, Personal, Research Grant: Vifor; Financial Interests, Personal, Expert Testimony: Merck Darmstadt; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Roche; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Ipsen; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Servier. J. Zhang: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. S. Soleymani: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. M. Lei: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb; Financial Interests, Personal, Other, Patent, Royalties, Other intellectual property: Bristol Myers Squibb. K. Kondo: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bristol Myers Squibb. J. Cleary: Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Roche; Financial Interests, Personal, Invited Speaker, Travel, Accommodations, Expenses: Aglos; Financial Interests, Personal, Invited Speaker, Travel, Accommodations, Expenses: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Merck; Financial Interests, Personal, Research Grant: Tesaro; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Esperas Pharma; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Institutional, Research Grant: Merus; Financial Interests, Institutional, Research Grant: Roche/Genentech; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb. R.J. Kelly: Financial Interests, Personal, Other, Consulting or Advisory Role: Novartis; Financial Interests, Personal, Other, Consulting or Advisory Role: Lilly; Financial Interests, Personal, Other, Consulting or Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Consulting or Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Other, Consulting or Advisory Role: Merck; Financial Interests, Personal, Other, Consulting or Advisory Role: Medscape; Financial Interests, Personal, Other, Consulting or Advisory Role: Pieris Pharmaceuticals; Financial Interests, Personal, Other, Consulting or Advisory Role: Takeda; Financial Interests, Personal, Other, Consulting or Advisory Role: OncLive; Financial Interests, Personal, Other, Consulting or Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Other, Consulting or Advisory Role: EMD Serono; Financial Interests, Personal, Other, Consulting or Advisory Role: Eisai; Financial Interests, Personal, Other, Consulting or Advisory Role: Peerview; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings